BRAF and metastatic melanoma: In particular, the baseline miR-1246/miR-485-3p ratio, which takes into consideration the levels of both miRNAs in each individual, appears to be a valuable biomarker to identify patients most likely to be unresponsive to targeted therapy or at higher risk for short-term PFS and mortality, and therefore is of potential clinical utility to improve, in addition to the presently well recognized prognostic factors, the management of patients with BRAF-mutant metastatic melanoma.